ID   OVCA433
AC   CVCL_0475
SY   OvCa433; OVCA 433; OvCa 433; OVCA-433; OVCA433_Bast; OVCAR-433; OVCAR 433; OVCAR433; SKOV-433; SK-OV-433; OV433
DR   BTO; BTO:0002566
DR   EFO; EFO_0006723
DR   MCCL; MCC:0000373
DR   ArrayExpress; E-MTAB-2706
DR   BioSample; SAMN03473291
DR   CCLE; OVCA433_OVARY
DR   Cell_Model_Passport; SIDM00966
DR   Cosmic; 924148
DR   Cosmic; 927568
DR   Cosmic; 1175882
DR   Cosmic; 1524355
DR   Cosmic; 1709258
DR   Cosmic-CLP; 1480367
DR   DepMap; ACH-002182
DR   GDSC; 1480367
DR   GEO; GSM95433
DR   GEO; GSM711706
DR   GEO; GSM851931
DR   GEO; GSM1670316
DR   GEO; GSM2474992
DR   PharmacoDB; OVCA433_1216_2019
DR   PRIDE; PXD003668
DR   Wikidata; Q54936989
RX   PubMed=1536252;
RX   PubMed=6346879;
RX   PubMed=7028788;
RX   PubMed=10972993;
RX   PubMed=11793438;
RX   PubMed=16382445;
RX   PubMed=22328975;
RX   PubMed=22585861;
RX   PubMed=22710073;
RX   PubMed=23415752;
RX   PubMed=24434149;
RX   PubMed=25485619;
RX   PubMed=27397505;
RX   PubMed=27561551;
RX   PubMed=28273451;
RX   PubMed=30894373;
WW   http://dpsc.ccbr.utoronto.ca/cancer/get_cellline.pl?cellline=OVCA433_Bast
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Doubling time: 102.24 hours (https://www.synapse.org/#!Synapse:syn2347014).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Exosome proteome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0.31%; Native American=1.3%; East Asian, North=0.31%; East Asian, South=0%; South Asian=0%; European, North=59.83%; European, South=38.24% (PubMed=30894373).
CC   Derived from sampling site: Ovary.
ST   Source(s): Cosmic-CLP; PubMed=22710073; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 12,13
ST   D13S317: 7,12
ST   D16S539: 12
ST   D18S51: 14
ST   D19S433: 13
ST   D21S11: 30
ST   D2S1338: 19,20
ST   D3S1358: 15,16
ST   D5S818: 11,12
ST   D7S820: 11,12
ST   D8S1179: 14,15
ST   FGA: 24
ST   Penta D: 13,14
ST   Penta E: 7,12
ST   TH01: 9
ST   TPOX: 9,11
ST   vWA: 16,18
DI   NCIt; C7550; Ovarian serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
OI   CVCL_IQ32 ! LAZ-444
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-07-20; Version: 25
//
RX   PubMed=1536252; DOI=10.1016/0002-9378(92)91697-9;
RA   Berchuck A., Rodriguez G., Olt G., Whitaker R., Boente M.P.,
RA   Arrick B.A., Clarke-Pearson D.L., Bast R.C. Jr.;
RT   "Regulation of growth of normal ovarian epithelial cells and ovarian
RT   cancer cell lines by transforming growth factor-beta.";
RL   Am. J. Obstet. Gynecol. 166:676-684(1992).
//
RX   PubMed=6346879; DOI=10.1016/0002-9378(83)90999-7;
RA   Berkowitz R., Kabawat S., Lazarus H., Colvin R.B., Knapp R.C.,
RA   Bast R.C. Jr.;
RT   "Comparison of a rabbit heteroantiserum and a murine monoclonal
RT   antibody raised against a human epithelial ovarian carcinoma cell
RT   line.";
RL   Am. J. Obstet. Gynecol. 146:607-612(1983).
//
RX   PubMed=7028788; DOI=10.1172/JCI110380;
RA   Bast R.C. Jr., Feeney M., Lazarus H., Nadler L.M., Colvin R.B.,
RA   Knapp R.C.;
RT   "Reactivity of a monoclonal antibody with human ovarian carcinoma.";
RL   J. Clin. Invest. 68:1331-1337(1981).
//
RX   PubMed=10972993; DOI=10.1002/1098-2744(200008)28:4<236::AID-MC6>3.0.CO;2-H;
RA   Rauh-Adelmann C., Lau K.-M., Sabeti N., Long J.P., Mok S.C., Ho S.-M.;
RT   "Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon
RT   12 deletion variant in malignant human ovarian, prostate, and breast
RT   cancer cell lines.";
RL   Mol. Carcinog. 28:236-246(2000).
//
RX   PubMed=11793438; DOI=10.1002/gcc.1221;
RA   Rao P.H., Harris C.P., Lu X.-Y., Li X.-N., Mok S.C., Lau C.C.;
RT   "Multicolor spectral karyotyping of serous ovarian adenocarcinoma.";
RL   Genes Chromosomes Cancer 33:123-132(2002).
//
RX   PubMed=16382445; DOI=10.1002/gcc.20300;
RA   Wang Y.C., Juric D., Francisco B., Yu R.X., Duran G.E., Chen G.K.,
RA   Chen X., Sikic B.I.;
RT   "Regional activation of chromosomal arm 7q with and without gene
RT   amplification in taxane-selected human ovarian cancer cell lines.";
RL   Genes Chromosomes Cancer 45:365-374(2006).
//
RX   PubMed=22328975; DOI=10.1158/2159-8290.CD-11-0170;
RA   Hanrahan A.J., Schultz N., Westfal M.L., Sakr R.A., Giri D.D.,
RA   Scarperi S., Janakiraman M., Olvera N., Stevens E.V., She Q.-B.,
RA   Aghajanian C., King T.A., de Stanchina E., Spriggs D.R., Heguy A.,
RA   Taylor B.S., Sander C., Rosen N., Levine D.A., Solit D.B.;
RT   "Genomic complexity and AKT dependence in serous ovarian cancer.";
RL   Cancer Discov. 2:56-67(2012).
//
RX   PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224;
RA   Marcotte R., Brown K.R., Suarez F., Sayad A., Karamboulas K.,
RA   Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.Y.,
RA   van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J.,
RA   Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P.,
RA   Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L.,
RA   Rottapel R., Neel B.G., Moffat J.;
RT   "Essential gene profiles in breast, pancreatic, and ovarian cancer
RT   cells.";
RL   Cancer Discov. 2:172-189(2012).
//
RX   PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017;
RA   Korch C., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K.,
RA   Lessey B.A., Jordan V.C., Bradford A.P.;
RT   "DNA profiling analysis of endometrial and ovarian cell lines reveals
RT   misidentification, redundancy and contamination.";
RL   Gynecol. Oncol. 127:241-248(2012).
//
RX   PubMed=23415752; DOI=10.1016/j.molonc.2012.12.007;
RA   Stordal B., Timms K., Farrelly A., Gallagher D., Busschots S.,
RA   Renaud M., Thery J., Williams D., Potter J., Tran T., Korpanty G.,
RA   Cremona M., Carey M.S., Li J., Li Y., Aslan O., O'Leary J.J.,
RA   Mills G.B., Hennessy B.T.;
RT   "BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one
RT   functionally deleterious BRCA1 mutation.";
RL   Mol. Oncol. 7:567-579(2013).
//
RX   PubMed=24434149; DOI=10.1016/j.bbrc.2013.12.070;
RA   Sinha A., Ignatchenko V., Ignatchenko A., Mejia-Guerrero S.,
RA   Kislinger T.;
RT   "In-depth proteomic analyses of ovarian cancer cell line exosomes
RT   reveals differential enrichment of functional categories compared to
RT   the NCI 60 proteome.";
RL   Biochem. Biophys. Res. Commun. 445:694-701(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H.,
RA   Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y.,
RA   Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D.,
RA   Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D.,
RA   Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S.,
RA   Zhang Z.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=27561551; DOI=10.1038/ncomms12645;
RA   Coscia F., Watters K.M., Curtis M., Eckert M.A., Chiang C.Y.,
RA   Tyanova S., Montag A., Lastra R.R., Lengyel E., Mann M.;
RT   "Integrative proteomic profiling of ovarian cancer cell lines reveals
RT   precursor cell associated proteins and functional status.";
RL   Nat. Commun. 7:12645-12645(2016).
//
RX   PubMed=28273451; DOI=10.1016/j.celrep.2017.02.028;
RA   Medrano M., Communal L., Brown K.R., Iwanicki M., Normand J.,
RA   Paterson J., Sircoulomb F., Krzyzanowski P., Novak M., Doodnauth S.A.,
RA   Saiz F.S., Cullis J., Al-Awar R., Neel B.G., McPherson J., Drapkin R.,
RA   Ailles L., Mes-Massons A.-M., Rottapel R.;
RT   "Interrogation of functional cell-surface markers identifies CD151
RT   dependency in high-grade serous ovarian cancer.";
RL   Cell Rep. 18:2343-2358(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//